stockrow
Friday 6 November 2026
Export FTRE’s income statement to Excel — free account
Fortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
21.95
1.49
+7.28%
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) P/E ratio
Fortrea Holdings Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 35.5× (December 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 18.0× | 0.00% |
| FY2021 | 18.0× | 0.00% |
| FY2020 | 18.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 13 more quarters | Free account |
Against its own ten years
Low 0.0×
High 35.5×
Ten-year median
0.0×
Current reading's percentile
85
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BHVN Biohaven Ltd. compare | n/m |
| FTRE Fortrea Holdings Inc. | n/m |
| VIR Vir Biotechnology, Inc. compare | n/m |
| TRAX First Tracks Biotherapeutics, Inc. compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| ZYME Zymeworks Inc. compare | n/m |
| IMNM Immunome, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | n/m |
| HRMY Harmony Biosciences Holdings, Inc. compare | 10.7× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)